Tarsus Pharmaceuticals (TARS) Cash from Investing Activities (2019 - 2026)

Tarsus Pharmaceuticals' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at -$58.6 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 67.6% year-over-year to -$58.6 million; the TTM figure through Mar 2026 stood at -$65.7 million (up 50.17% YoY), while the FY2025 annual figure was -$42.1 million, up 78.86% from the prior year.
• Cash from Investing Activities was -$58.6 million for Q1 2026 at Tarsus Pharmaceuticals, down from $49.3 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $64.1 million in Q2 2023 to a low of -$102.2 million in Q1 2024.
• Historically, Cash from Investing Activities has averaged -$17.9 million across 5 years, with a median of -$4.7 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities tumbled 47112.4% in 2022, then soared 52634.43% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at -$87.2 million in 2022, then jumped by 120.47% to $17.8 million in 2023, then slumped by 433.75% to -$59.6 million in 2024, then jumped by 182.71% to $49.3 million in 2025, then tumbled by 218.85% to -$58.6 million in 2026.
• The last three Cash from Investing Activities figures came in at -$58.6 million (Q1 2026), $49.3 million (Q4 2025), and -$4.7 million (Q3 2025), per Business Quant data.